Text and Data Mining valid from 2019-10-24
Received: 9 May 2019
Accepted: 26 September 2019
First Online: 24 October 2019
Ethics approval and consent to participate
: This study (NCT01343043) was conducted in compliance with the Declaration of Helsinki, and in accordance with local legal and regulatory requirements. The protocol was approved by each center’s Institutional Review Board, and informed consent forms were obtained for all patients.
: All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript. The manuscript is original, has not already been published, and is not currently under consideration by another journal.
: IR, DEL, RDM, RW, SF, DN, GB, NB, AJT, LM, JMN, MI, TT, EVW, KC, RA, GKB, and SB: employees of Adaptimmune and have stock or other ownership interests in Adaptimmune.JG: NoneCLM: Consulting for Adaptimmune, GlaxoSmithKline, Allogene, Nektar, Vor, PACT, Unum, Bryologyx, Apricity, Roche, Lyell. Equity in Allogene, Vor, PACT, Unum, Lyell. Research Funding from: Obsidian.SPD: Consulting for Amgen, EMD Serono, Nektar, travel support from AdaptimmuneDMA: NoneWAC: Speaker’s bureau and research funding from Novartis, data safety monitoring board for AdvenchenGDD: NoneBAVT: Basic science grant funding from Pfizer, Tracon, and Merck; consulting fees from Epizyme, Lilly, CytRX, Janssen, Immune Design, Daiichi Sankyo, Plexxicon and Adaptimmune; speaking fees from Caris, Janseen, and LillyMD: Consulting and speaker’s bureau for Eisai and LillySG: Research and/or clinical trial support from Novartis, Servier, Adaptimmune, and Kite. Consulting, study steering committees, or scientific advisory boards: Novartis, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen, and Roche.ARAR: Consulting for Lilly, Merck, Boehringer Ingelheim, research funding from CASI Pharmaceuticals, Boehringer IngelheimBW: Research support from Merck, Pfizer, Agenus, and consulting for Lilly and Immune Design